The relapse of superficial bladder tumours can be prevented, after endoscopic treatment, by intravesical chemo and immunoprophylaxis. In the first 6 months of 1991, 14 patients (13 males, 1 female, average age 58.3) were treated endoscopically for superficial bladder tumours, which had been detected on average 3.5 years earlier. Intravesical treatment was with 50 mg Epirubicin and, after 3 hours, alpha-2b Interferon once a week for 8 weeks. The patients had a hematological and cystoscopic control every 3 months for one year. A decrease in tumour recurrence was noted at the first endoscopic control, then only slow growth of superficial bladder tumour recurrence was observed.
Blinst Italian Cooperative Group: Intravescical Doxorubicine for the prophylaxis of superficial bladder tumors. Cancer, 54: 756–761, 1984.
2.
LeanderssonT., NordfelthR., LundgreeE.: Antiproliferative effect of (2’ – 5’) oligoadenylate distruct from that of interferon in lymphoid cells. Bichem. Biophyd. Res. Comm., 107: 511–513, 1982.
3.
RizzoM., BartolettiR., SelliC., CariniM., SicignanoA., MassiminiG.: Terapia intravescicale con interferone alfa 2A nel carcinoma superficiale della vescica. Risultati preliminari in uno studio di fase II. Acta Urol. Ital., 2: 111–115, 1988.
4.
SteinB.S., KendallA.R.: Blood group antigens and bladder carcinoma: a prospective. Urology, 134: 40–45, 1985.
5.
ShortliffeL.D., FreihaF.S., HanniganJ.F.: Intravesical interferon therapy for carcinoma in situ and transitional cell carcinoma of the bladder. J. Urol., 131: 171–175, 1984.
6.
TortiF.M., LumB.L.: Superficial bladder cancer risk of recurrence and potential role for interferon therapy. Cancer, 59: 613–617, 1987.
7.
ZenicoT., TamburiniC., FabbriF., MaltoniM., ZoliM., MaltoniG.: Carcinomi superficiali della vescica: profilassi delle recidive con 4 epi-rxubicina. Romagna Medica, 39: 3–7, 1987.
